# Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

> **NCT04926285** · PHASE1 · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 6 (actual)

## Conditions studied

- Relapsed or Refractory Hematologic Malignancies

## Interventions

- **DRUG:** Omacetaxine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04926285
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-01-29
- **Final completion:** 2025-02-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926285, "Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04926285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*